CA IX siRNA (h) from Santa Cruz Biotechnology, Inc. | Biocompare.com

Supplier Images

CA IX siRNA (h)

Be the first to write a review!

Citations:

Supplier Page from
Santa Cruz Biotechnology, Inc. for
CA IX siRNA (h)

Description

CA IX siRNA (h)

Product Specs
ItemCA IX siRNA (h)
CompanySanta Cruz Biotechnology, Inc.
Price $293.00Supplier Page View Company Product Page
Catalog Numbersc-29869
Quantity10 µM
TypesiRNA/dsRNA
NCBI Gene AliasesCAIX, MN
NCBI Full Gene Namecarbonic anhydrase 9
Specieshuman
Gene Namecarbonic anhydrase IX

Add to Compare List

Santa Cruz Biotechnology, Inc.

Santa Cruz Biotechnology, Inc.

10410 Finnell Street

Dallas, Texas 75220

United States

Phone: 1-800-457-3801
831-457-3801

Company Profile

Website: http://www.scbt.com/

(1) Suppression of Tumor Growth and Cell Migration by Indole-Based Benzenesulfonamides and Their Synergistic Effects in Combination with DoxorubicinInternational journal of molecular sciencesAugust 31, 2022Nguyen PL, Elkamhawy A, Choi YH, Lee CH, Lee K, Cho J.

(2) Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinomaUrologic oncologyAugust 1, 2021Todenhöfer T, Gibb EA, Seiler R, Kamyabi A, Hennenlotter J, McDonald P, Moskalev I, Stewart C, Gao J, Fazli L, et al.

(3) ZEB1 transcriptionally regulated carbonic anhydrase 9 mediates the chemoresistance of tongue cancer via maintaining intracellular pHMolecular cancerApril 15, 2015Zheng G, Peng C, Jia X, Gu Y, Zhang Z, Deng Y, Wang C, Li N, Yin J, Liu X, et al.

(4) Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cellsOncotargetMarch 30, 2015Kopecka J, Campia I, Jacobs A, Frei AP, Ghigo D, Wollscheid B, Riganti C.

(5) Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cellsCell cycle (Georgetown, Tex.)June 1, 2013Fiaschi T, Giannoni E, Taddei ML, Cirri P, Marini A, Pintus G, Nativi C, Richichi B, Scozzafava A, Carta F, et al.

(6) Poly(ethylene glycol)-grafted polyethylenimine modified with G250 monoclonal antibody for tumor gene therapyHuman gene therapyFebruary 1, 2010Duan Y, Yang C, Zhang Z, Liu J, Zheng J, Kong D.

Be the First to Write a Review!